Chronic Hepatitis and Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 50
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and it is the second most common cause of tumor-related death worldwide. HCC is frequently associated with liver cirrhosis, which is caused, in the majority of cases, by sustained damage to the liver cells, leading to inflammation and fibrosis development.
Although the etiologies of chronic hepatitis are diverse, including viral hepatitis, MASLD, and alcohol consumption, a chronically inflamed state of the liver is the common driver of liver cirrhosis, consequently causing an increase in the risk of developing HCC.
In this scenario, the role of the underlying chronic hepatitis is crucial in the management of HCC, as it has a direct influence on several aspects, including the surveillance regimen used, clinical management, and the probability of benefitting from different treatments.
In this Special Issue, we welcome original research articles and reviews that aim to dissect the role of background chronic hepatitis and its relationship with HCC, including the relevance of the etiological treatments of the underlying chronic hepatitis, the differences in the mechanism of carcinogenesis, and the centrality of liver inflammation and liver dysfunction in the response to different treatments for HCC. Epidemiological and clinical articles will also be taken into consideration.
Dr. Bernardo Stefanini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HCC
- hepatic disfunction
- chronic hepatitis
- viral hepatitis
- liver inflammation
